InCephalo Therapeutics

InCephalo Therapeutics is a private, preclinical-stage biotech based in Basel, Switzerland, developing a novel class of biologics for central nervous system (CNS) diseases. Its core innovation, the C-Lock™ platform, engineers proteins to be retained exclusively within the brain compartment, enabling high-dose, localized immune activation without the severe systemic side effects that have plagued previous approaches. With lead asset InC01 targeting glioblastoma and supported by strong preclinical data and EMA Orphan Drug Designation, the company is positioned to address a critical unmet need with a potentially transformative treatment modality.

C-Lock™ platform engineers biologics with reduced FcRn binding for brain retention, tissue anchoring for extended local effect, and rapid systemic clearance for safety, enabling compartment-locked delivery of potent payloads like cytokines to the CNS.

InCephalo competes in the glioblastoma space against standard chemoradiation, emerging systemic therapies, and other local delivery approaches (e.g., viral gene therapy, implanted polymers). Its primary differentiation is the specific engineering for compartment-locked retention and rapid systemic degradation, a novel approach aimed at overcoming the toxicity that has limited potent immunotherapies for brain cancer.